Th e search for interventions to reduce avoidable readmissions aft er an exacerbation of COPD has attracted substantial attention aft er the Centers for Medicare & Medicaid Services included COPD exacerbations in its Hospital Readmissions Reduction Program. 1 We read with great interest the study by Jennings et al 2 in a recent issue of CHEST (May 2015) and applaud the authors for conducting a randomized clinical trial to test the eff ects of a predischarge care bundle. Th e study demonstrated a numerically lower but not statistically signifi cant risk of 30-day readmissions or visits to the ED in the intervention group (risk diff erence, 2 3.4%; 95% CI, 2 15.7% to 8.8%). Th e authors acknowledged several potential limitations in the study design, including relying on the primary team to implement interventions directed at risk factors identifi ed by the researchers and the selective eligibility criteria.
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We propose another limitation. Th e study used a highly optimistic eff ect size (50% reduction from 20% to 10%) for sample size calculations and was, therefore, underpowered to test the hypothesis that a predischarge care bundle can reduce postdischarge readmissions or ED visits. Why was this large eff ect size proposed? Overall, the study highlights the continued need to identify interventions that reduce readmissions in patients with COPD exacerbations. 
Response

To the Editor:
We appreciate the comments by Dr Zaidi and colleagues on our recent article in CHEST . 1 Th ey ask whether the eff ect size in our study from 20% to 10% reduction in readmissions was overly optimistic. Th ere is a paucity of data in the literature to guide us as to what an expected magnitude of reduction in 30-day readmission rates should be. Importantly, choosing an eff ect size should be based on what is "clinically meaningful. " Unfortunately, this can oft entimes be challenging and subjective. In the absence of a specifi c intervention, rates of 30-day readmissions for COPD range from 7% to 22%. 2 We, therefore, chose an absolute reduction of 10%, given our baseline prestudy admission rate of 20% at Henry Ford.
Would choosing a smaller eff ect size have shown us a diff erence between groups? Perhaps not. While the point estimate of the risk diff erence was 2 3.5%, the CI shows that true risk diff erence may very well be 1 8.8% in favor of no intervention. Nonetheless, had the larger sample size resulted in statistical signifi cance for this small risk diff erence, one might question the clinical signifi cance of an intervention as only marginally favorable.
